Q1 Earnings Estimate for Liquidia Issued By Lifesci Capital

Liquidia Co. (NASDAQ:LQDA) – Analysts at Lifesci Capital issued their Q1 2025 EPS estimates for Liquidia in a research note issued to investors on Wednesday, March 19th. Lifesci Capital analyst C. Jubinville anticipates that the company will earn ($0.37) per share for the quarter. The consensus estimate for Liquidia’s current full-year earnings is ($1.51) per share.

Several other research firms have also issued reports on LQDA. Needham & Company LLC increased their price objective on shares of Liquidia from $19.00 to $25.00 and gave the stock a “buy” rating in a research report on Thursday. Wells Fargo & Company initiated coverage on shares of Liquidia in a report on Friday, December 20th. They set an “overweight” rating and a $20.00 price target for the company. Scotiabank raised their price target on shares of Liquidia from $30.00 to $34.00 and gave the company a “sector outperform” rating in a report on Thursday. Finally, HC Wainwright reaffirmed a “buy” rating and set a $29.00 price target on shares of Liquidia in a report on Thursday. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, Liquidia presently has an average rating of “Buy” and a consensus target price of $26.63.

Liquidia Stock Down 2.1 %

Liquidia stock opened at $15.12 on Friday. Liquidia has a 52-week low of $8.26 and a 52-week high of $16.99. The firm has a fifty day moving average of $14.79 and a 200-day moving average of $12.18. The firm has a market capitalization of $1.28 billion, a P/E ratio of -9.28 and a beta of 0.07.

Liquidia (NASDAQ:LQDA) last released its quarterly earnings data on Wednesday, March 19th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.08). Liquidia had a negative return on equity of 163.21% and a negative net margin of 765.38%. The business had revenue of $2.92 million during the quarter, compared to analyst estimates of $4.60 million.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the stock. California State Teachers Retirement System lifted its position in shares of Liquidia by 17.5% in the 4th quarter. California State Teachers Retirement System now owns 51,928 shares of the company’s stock worth $611,000 after buying an additional 7,725 shares during the last quarter. Toronto Dominion Bank bought a new position in shares of Liquidia in the 4th quarter worth about $235,000. Alpine Global Management LLC lifted its position in shares of Liquidia by 50.0% in the 4th quarter. Alpine Global Management LLC now owns 150,000 shares of the company’s stock worth $1,764,000 after buying an additional 50,000 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in shares of Liquidia by 26.9% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 105,734 shares of the company’s stock worth $1,243,000 after buying an additional 22,445 shares during the last quarter. Finally, Whitefort Capital Management LP lifted its position in shares of Liquidia by 16.8% in the 4th quarter. Whitefort Capital Management LP now owns 1,987,245 shares of the company’s stock worth $23,370,000 after buying an additional 285,220 shares during the last quarter. 64.54% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Liquidia

In other Liquidia news, CFO Michael Kaseta sold 23,370 shares of the stock in a transaction on Tuesday, January 14th. The shares were sold at an average price of $11.78, for a total transaction of $275,298.60. Following the transaction, the chief financial officer now directly owns 401,755 shares in the company, valued at $4,732,673.90. This represents a 5.50 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Rajeev Saggar sold 6,249 shares of the stock in a transaction on Tuesday, January 14th. The shares were sold at an average price of $11.78, for a total transaction of $73,613.22. Following the transaction, the insider now owns 270,388 shares in the company, valued at $3,185,170.64. This trade represents a 2.26 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 71,245 shares of company stock worth $843,326 in the last ninety days. 30.10% of the stock is owned by insiders.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).